Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS.

Cofiell, Roxanne; Kukreja, Anjli; Bedard, Krystin; Yan, Yan; Mickle, Angela P; Ogawa, Masayo; Bedrosian, Camille L; Faas, Susan J

Cofiell, Roxanne; Kukreja, Anjli; Bedard, Krystin; Yan, Yan; Mickle, Angela P; Ogawa, Masayo; Bedrosian, Camille L; Faas, Susan J.

Affiliation

Cofiell R; Alexion Pharmaceuticals, Inc., Cheshire, CT.
Kukreja A; Alexion Pharmaceuticals, Inc., Cheshire, CT.
Bedard K; Alexion Pharmaceuticals, Inc., Cheshire, CT.
Yan Y; Alexion Pharmaceuticals, Inc., Cheshire, CT.
Mickle AP; Alexion Pharmaceuticals, Inc., Cheshire, CT.
Ogawa M; Alexion Pharmaceuticals, Inc., Cheshire, CT.
Bedrosian CL; Alexion Pharmaceuticals, Inc., Cheshire, CT.
Faas SJ; Alexion Pharmaceuticals, Inc., Cheshire, CT.

Blood ; 125(21): 3253-62, 2015 May 21.

Article in En | MEDLINE | ID: mdl-25833956

Subject(s)

Antibodies, Monoclonal, Humanized/therapeutic use; Atypical Hemolytic Uremic Syndrome/drug therapy; Acute Kidney Injury/drug therapy; Acute Kidney Injury/etiology; Adult; Atypical Hemolytic Uremic Syndrome/blood; Atypical Hemolytic Uremic Syndrome/complications; Biomarkers/blood; Complement Activation/drug effects; Endothelium, Vascular/drug effects; Female; Humans; Inflammation/drug therapy; Inflammation/etiology; Male; Thrombosis/drug therapy; Thrombosis/etiology

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / Atypical Hemolytic Uremic Syndrome Type of study: Clinical_trials / Etiology_studies Limits: Adult / Female / Humans / Male Language: En Journal: Blood Year: 2015 Document type: Article Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google